By D. W. G. Kalani Tharanga, JadeTimes News
BiologIC Technologies, a company based in Cambridgeshire, is pioneering a revolutionary method for manufacturing medicines in space. The UK Space Agency (UKSA) recently announced that BiologIC Technologies will be among the recipients of a £65 million fund dedicated to developing new technologies for testing aboard the International Space Station (ISS). The unique microgravity environment of space offers distinct advantages for health research, such as studying age related diseases and potentially cultivating human organs for transplants, making space an ideal setting for such experiments.
Richard Vellacott, CEO of BiologIC Technologies, expressed his enthusiasm for the project, stating, “It’s a privilege to help the UK lead the way.” The company aims to adapt its advanced system for developing and manufacturing vaccines and gene therapies to function in space. This adaptation involves ensuring the system can withstand the extreme conditions of launch and the microgravity environment, where liquids float and traditional containment methods must be rethought. Vellacott highlighted the broader potential of their system, noting that it could also be used to produce food and raw materials from basic biological ingredients, which is crucial for the efficiency and versatility needed on the ISS.
The Broader Impact of Space Research on Earth
The resurgence of interest and investment in space exploration, often referred to as 'Space Race 2.0,' is no longer solely about reaching other planets but about enabling sustainable human life beyond Earth. Central to these efforts is ensuring astronauts can be self sufficient, which is why UKSA is funding various innovative projects like the one undertaken by BiologIC Technologies.
Libby Jackson, head of space exploration at UKSA, emphasized the broader significance of space research. She noted that removing the force of gravity allows researchers to gain new insights, which can lead to advancements benefiting life on Earth. For instance, studying cellular aging in space, where cells age faster, can expedite the development of new treatments for age related conditions. Additionally, the possibility of growing human organs in microgravity could revolutionize organ transplantation, offering new hope for patients worldwide.
Moreover, the techniques developed for space could eventually be applied on Earth to produce raw materials sustainably, reducing the reliance on imports and contributing to long term ecological balance. The UK’s strong capabilities in space science and technology, as highlighted by Jackson, underpin these endeavors, ensuring that advancements made in space can translate into tangible benefits for everyday life on Earth.
The funding for these initiatives was issued under the previous government, with the announcement delayed by the general election. While a specific date for the mission to take BiologIC's technology to space has not been set, Vellacott remains optimistic about the impact of their work, reiterating, “It’s a privilege to help the UK lead the world in engineering biology and space technology.”
